Testing a brain implant that helps people with speech loss communicate
Tests a brain-computer device that turns speech attempts into computer text for adults with paralysis.
Plain-language title generated from the registry record
Registry title: Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
Key facts
- Where
- Sacramento, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06094205, who can take part
Where in United States
- University of California - DavisSacramento, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leigh R. Hochberg, MD, PhD.
- Trial code
- NCT06094205
- Record updated
- 1 December 2025
- Original description
The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.Read full original descriptionShow less
Understanding and Restoring Speech Production Using an Intracortical Brain-computer Interface
The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.
Inclusion: Between 18 and 80 years of age; Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders; Complete or incomplete tetraplegia (quadriplegia); Must live within a three-hour drive of the Study site and geographically stable for at least 15 months after enrollment; (There are additional inclusion criteria).
Exclusion: Chronic oral or intravenous steroids or immunosuppressive therapy; Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses; Other serious disease or disorder that could seriously affect ability to participate in the study; (There are additional exclusion criteria).